{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progression-Free+Survival&page=2", "query": { "condition": "Progression-Free Survival", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Progression-Free+Survival&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T16:04:53.099Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01837095", "title": "Dose Escalation of POL6326 in Combination With Eribulin in Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "POL6326", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Polyphor Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "FEMALE", "summary": "18 Years to 55 Years · Female only" }, "enrollment_count": 54, "start_date": "2013-06", "completion_date": "2018-08", "has_results": false, "last_update_posted_date": "2018-09-14", "last_synced_at": "2026-07-23T16:04:53.099Z", "location_count": 5, "location_summary": "Kansas City, Kansas • St Louis, Missouri • Lebanon, New Hampshire + 2 more", "locations": [ { "city": "Kansas City", "state": "Kansas" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "New York", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01837095" }, { "nct_id": "NCT00773383", "title": "A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "RG1507", "type": "DRUG" }, { "name": "erlotinib [Tarceva]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2008-11", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-07-23T16:04:53.099Z", "location_count": 6, "location_summary": "Santa Monica, California • Miami, Florida • Boston, Massachusetts + 1 more", "locations": [ { "city": "Santa Monica", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00773383" }, { "nct_id": "NCT06273176", "title": "The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Glioblastoma, IDH-wildtype", "Glioblastoma", "Glioblastoma Multiforme of Brain", "Astrocytoma, Malignant", "Brain Neoplasms", "Brain Neoplasms, Adult, Malignant", "Brain Neoplasms, Adult", "Recurrent Adult Brain Tumor", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Awake mapping under local anesthesia", "type": "PROCEDURE" }, { "name": "Asleep mapping under general anesthesia", "type": "PROCEDURE" }, { "name": "Resection under general anesthesia without mapping", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Erasmus Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "90 Years", "sex": "ALL", "summary": "Up to 90 Years" }, "enrollment_count": 225, "start_date": "2023-01-01", "completion_date": "2028-01-01", "has_results": false, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-07-23T16:04:53.099Z", "location_count": 2, "location_summary": "San Francisco, California • Boston, Massachusetts", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06273176" }, { "nct_id": "NCT00288275", "title": "Correlation of the Chemoresponse Assay With PFS in Patients With Recurrent Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Peritoneal Neoplasms" ], "interventions": [], "intervention_types": [], "sponsor": "Precision Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 256, "start_date": "2004-07", "completion_date": "2012-10", "has_results": false, "last_update_posted_date": "2012-10-05", "last_synced_at": "2026-07-23T16:04:53.099Z", "location_count": 36, "location_summary": "Irvine, California • Los Angeles, California • New Haven, Connecticut + 30 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00288275" }, { "nct_id": "NCT03078855", "title": "A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Follicular Lymphoma", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma", "Mucosal-Associated Lymphoid Tissue Lymphoma" ], "interventions": [ { "name": "Vitamin D", "type": "DIETARY_SUPPLEMENT" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "BIOLOGICAL", "OTHER" ], "sponsor": "Jonathan Friedberg", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 211, "start_date": "2017-09-07", "completion_date": "2024-07-02", "has_results": true, "last_update_posted_date": "2024-09-04", "last_synced_at": "2026-07-23T16:04:53.099Z", "location_count": 7, "location_summary": "Miami, Florida • Atlanta, Georgia • Iowa City, Iowa + 4 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03078855" }, { "nct_id": "NCT06624371", "title": "Atovaquone Combined With Radiation in Children With Malignant Brain Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "High-grade Glioma", "Medulloblastoma", "Diffuse Intrinsic Pontine Glioma", "Diffuse Midline Glioma, H3 K27M-Mutant" ], "interventions": [ { "name": "Atovaquone", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "2 Years to 25 Years" }, "enrollment_count": 18, "start_date": "2025-03-28", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-07-23T16:04:53.099Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06624371" }, { "nct_id": "NCT00338286", "title": "A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Neoplasm Metastasis" ], "interventions": [ { "name": "Standard supportive care (packed RBC transfusion)", "type": "OTHER" }, { "name": "epoetin alfa + packed RBC transfusion", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "FEMALE", "summary": "18 Years to 99 Years · Female only" }, "enrollment_count": 2098, "start_date": "2006-03-02", "completion_date": "2017-01-31", "has_results": true, "last_update_posted_date": "2018-03-19", "last_synced_at": "2026-07-23T16:04:53.099Z", "location_count": 14, "location_summary": "Anaheim, California • Gainesville, Florida • Miami, Florida + 11 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "New Port Richey", "state": "Florida" }, { "city": "Rockledge", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00338286" }, { "nct_id": "NCT01282931", "title": "Patient-reported Outcome Questionnaire for Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Health Outcomes Solutions", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 200, "start_date": "2011-01", "completion_date": "2011-03", "has_results": false, "last_update_posted_date": "2011-10-12", "last_synced_at": "2026-07-23T16:04:53.099Z", "location_count": 1, "location_summary": "Winter Park, Florida", "locations": [ { "city": "Winter Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01282931" }, { "nct_id": "NCT00719303", "title": "Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Malignant Ovarian Brenner Tumor", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Seromucinous Carcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7", "Undifferentiated Fallopian Tube Carcinoma", "Undifferentiated Ovarian Carcinoma" ], "interventions": [ { "name": "Behavioral Dietary Intervention", "type": "BEHAVIORAL" }, { "name": "Compliance Monitoring", "type": "BEHAVIORAL" }, { "name": "Counseling", "type": "OTHER" }, { "name": "Educational Intervention", "type": "OTHER" }, { "name": "Exercise Intervention", "type": "BEHAVIORAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BEHAVIORAL", "OTHER" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1070, "start_date": "2012-06-18", "completion_date": null, "has_results": false, "last_update_posted_date": "2018-02-19", "last_synced_at": "2026-07-23T16:04:53.099Z", "location_count": 687, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 452 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00719303" }, { "nct_id": "NCT06520345", "title": "The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer" ], "interventions": [ { "name": "177Lu-TLX591", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Telix Pharmaceuticals (Innovations) Pty Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 520, "start_date": "2024-07-26", "completion_date": "2030-12", "has_results": false, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-07-23T16:04:53.099Z", "location_count": 9, "location_summary": "Orange, California • Miami, Florida • Glen Burnie, Maryland + 6 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Glen Burnie", "state": "Maryland" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06520345" } ] }